Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

키워드

참고문헌 (16)

1. Grace Lai-Hung Wong, "Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend", Clinical and Molecular Hepatology, 24(2), pp.108~113 (2018), 대한간학회
2. Bertoletti A, "Adaptive immunity in HBV infection", J Hepatol, 64(1 Suppl), pp.S71~S83 (2016)
3. European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
4. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
5. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
6. Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
7. Lilian Yan Liang, "Unmet need in chronic hepatitis B management", Clinical and Molecular Hepatology, 25(2), pp.172~180 (2019), 대한간학회
8. Lee HW, "Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B", Eur J Intern Med, 84, pp.68~73 (2021)
9. Kim GA, "High risk of hepatocellular carcinoma and death in patients with immunetolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
10. Mi Young Jeon, "Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B", Clinical and Molecular Hepatology, 27(2), pp.295~304 (2021), 대한간학회[DOI]
11. Wong GL, "Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B", J Hepatol, 69, pp.793~802 (2018)
12. Hagström H, "Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease", J Hepatol, 73, pp.1023~1029 (2020)
13. Liang LY, "Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma", Aliment Pharmacol Ther, 49, pp.1509~1517 (2019)
14. Chang Y, "Nucleos(t)ide analogue treatment for patients with hepatitis B virus (HBV) e antigen-positive chronic HBV genotype C infection: a nationwide, multicenter, retrospective study", J Infect Dis, 216, pp.1407~1414 (2017)
15. Chan HL, "Effects of tenofovir disoproxil fumarate in hepatitis B e antigenpositive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA", Gastroenterology, 146, pp.1240~1248 (2014)
16. Wong GL, "Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment", Gastroenterology, 144, pp.933~944 (2013)

관련 논문AI추천